EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 [Yahoo! Finance]
EyePoint, Inc. (EYPT)
Last eyepoint, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
– Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing expected in Q1 2026 – – Presenting at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at a.m. PT – WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today reported a corporate update and anticipated 2026 pivotal milestones for its lead product candidate, DURAVYU ™ (vorolanib intravitreal insert). “Following an incredibly successful year of execution in 2025, EyePoint is positioned to deliver on key priorities across both of our late-stage programs, wet AMD and DME, in 2026,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. “As we prepare for a milestone-rich year, we continue to be guided by scientific
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026GlobeNewswire
- EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains [Yahoo! Finance]Yahoo! Finance
- Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at TD Cowen to a "strong-buy" rating.MarketBeat
- EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 11/5/25 - Miss
EYPT
Sec Filings
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- EYPT's page on the SEC website